Overview

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

Status:
RECRUITING
Trial end date:
2027-09-08
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.
Phase:
PHASE2
Details
Lead Sponsor:
Celgene